XML 66 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

Summary of Quarterly Financial Data

The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December 31, 2018.

		2018																2017
		Q1				Q2				Q3				Q4				Q1				Q2				Q3				Q4
Revenues		$	12,637			$	21,416			$	23,562			$	26,837			$	3,425			$	8,253			$	11,812			$	13,077
Expenses			33,634				40,556				39,803				47,609				20,217				21,021				24,847				26,843
Net loss			(20,187	)			(16,640	)			(12,843	)			(19,219	)			(16,632	)			(12,491	)			(12,354	)			(13,091	)
Net loss attributable to non-controlling interest			—				—				—				(555	)			—				—				—				—
Net loss attributable to Sangamo Therapeutics, Inc.			(20,187	)			(16,640	)			(12,843	)			(18,664	)			(16,632	)			(12,491	)			(12,354	)			(13,091	)
Basic and Diluted Net loss per share attributable to Sangamo Therapeutics, Inc.			(0.23	)			(0.17	)			(0.13	)			(0.18	)			(0.23	)			(0.17	)			(0.15	)			(0.15	)

X

- References

No definition available.

+ Details

Name:	us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109225645&loc=d3e1280-108306

+ Details

Name:	us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration